Advances in the diagnosis and treatment of the infection by the hepatitis B virus;Avances en el diagnóstico y tratamiento de la infección por el virus de la hepatitis B

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 9, 2004, Pages 539-549

  Núñez, Marina ^a   García Samaniego, Javier ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Anti HBV therapy; Chronic hepatitis; HIV

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2A INTERFERON; AMDOXOVIR; ANTIVIRUS AGENT; CLEVUDINE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MORBIDITY; MORTALITY; RELAPSE; REVIEW; SEROCONVERSION; SEROPREVALENCE; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 9644308189     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13067622     Document Type: Review

References (54)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures: a review. J Viral Hepat 2004;11:97-107.
2. Lai C, Ratziu V, Yuen M, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-94.
3. Alter M. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39-46.
4. Shaw T, Locarnini S. Hepatitis B. En: Encyclopedia of Gastroenterology. Elsevier, 2004.
5. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47-58.
6. Ganem D, Prince A. Hepatitis B virus infection. Natural History and clinical consequences. N Engl J Med 2004;350:1118-29.
7. Chu C, Hussein M, Lok A. Quantitative serum HBV-DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-15.
8. Geier A, Dietrich C, Gartung C. Antiviral therapy in HBeAg-positive hepatitis B with normal aminotransferase levels. Hepatology 2003;37:712-3.
9. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2001;34:1225-41.
10. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV-DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:1309-19.
11. Keeffe E, Dieterich D, Han S, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clinical Gastroenterol Hepatol 2004;2:87-106.
12. Cooksley W, Piratvisuth T, Lee S, et al. Peginterferon alfa-2a (40KD): An advance in the treatment of HBeAg-Positive Chronic Hepatitis B. J Viral Hepat 2003;10:298-305.
13. Brunetto M, Oliveri F, Colombatto P, Coco B, Ciccorossi P, Bonino F. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol 2003;39(Suppl 1):l64-7.
14. Tatulli I, Francavilla R, Rizzo G, et al. Lamivudine and alpha-interferon in combination long-term for precore mutant chronic hepatitis B. J Hepatol 2001;35:805-10.
15. Schiff E, Karayalcin S, Dienstag J, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon non-responders. J Hepatol 2003;38:818-26.
16. Barbaro G, Zechini F, Pellicelli A, et al. Long-term efficacy of interferon alpha-2b and lamivudine combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter randomized trial. J Hepatol 2001;35:406-11.
17. Sung J, Chan H, Hui A, Wong V, Liew C, Chim A, et al. Combination of peginterferon alfa-2b and lamivudine is superior to lamivudine alone in the treatment of chronic hepatitis B [abstract 410]. Gastroenterology 2004;126(Suppl 2):A-682.
18. Peters M, Hann H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
19. Liaw Y, Leung N, Chang T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
20. Leung N, Lai C, Chang T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
21. Westland C, Villeneuve J, Terrault N, Zoulim F, Brosgart C, Wulfsohn M, et al. Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipivoxil treatment [abstract #10]. Hepatology 2003;38(Suppl 1):160A.
22. Chang T, Hadziyannis S, Cianciara J, Rizzeto M, Schiff G, Pastore G, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine [abstract 550]. Hepatology 2002;36:300A.
23. Kanwal F, Spiegel B, Dulai G, Martin P, Bralnek T, et al. Adefovir salvage therapy is cost-effective in chronic hepatitis B [abstract 6]. Gastroenterology 2004;126(Suppl 2):A-661.
24. Soriano V, Martín-Carbonero L, García-Samaniego J, Puoti M. Mortality due to viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis 2001;33:1793-4.
25. Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6.
26. Laure F, Zagury D, Saimont A, et al. Hepatitis B virus DNA sequences in lymphoid cells from patients with AIDS and AIDS-related complex. Science 1985;229:561-3.
27. Gómez-Gonzalo M, Carretero M, Rullas J, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals. J Biol Chem 276;38:35435-43.
28. Gilson R, Hawkins A, Beecham M, et al. Interaction between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997;11:597-606.
29. Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in HIV-infected subjects. AIDS Clin Rev 2002;4:27-35.
30. Eskil A, Magnus P, Petereen G, et al. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 1992;6:571-4.
31. Weller I, Brown A, Morgan B, et al. Spontaneous loss of HBeAg and the prevalence of HTLV-III/LAV infection in a cohort of homosexual hepatitis B virus carriers and the implication for antiviral therapy. J Hepatol 1986;3 (Suppl 2):9-16.
32. Colin J, Cazals-Hatem D, Loriot A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
33. Núñez M, Ríos P, Pérez-Olmeda M, Soriano V. Lack of "occult" hepatitis B virus infection in HIV-infected patients. AIDS 2002;16:2099-101.
34. Bodsworth N, Donovan B, Nightingale B. The effects of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-82.
35. Perrillo R, Regenstein F, Roodman S. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann Intern Med 1986;105:382-3.
36. Bonacini M, Govindarajan S, Redeker A. Human immunodeficiency virus infection does not alter serum transaminases and hepatitis B virus (HBV) DNA in homosexual patients with chronic HBV infection. Am J Gastroenterol 1991;86:570-3.
37. Housset C, Pol S, Carnot P, et al. Interactions between human immunodeficiency virus-1, hepatitis delta and hepatitis B virus infection in 260 chronic carriers of hepatitis B virus. Hepatology 1992;15:578-83.
38. Wong D, Cheung A, O'Rourke Naylor C, Detsky A, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
39. Di Martino V, Thevenot T, Colin J, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123:1812-22.
40. Dore J, Cooper D, Barret C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus hepatitis B coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis 1999;180:607-13.
41. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus infected patients. Hepatology 1999;30:1303-6.
42. Hoff J, Bani-Sadr F, Gassin M, et al. Evaluation of chronic hepatitis B virus (HBV) infection in co-infected patients receiving lamivudine as component of anti-human immunodeficiency virus regimen. Clin Infect Dis 2001;32:963-9.
43. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman K. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;285:1032-5.
44. Dore G, Cooper D, Pozniak A, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185-92.
45. Van Bommel F, Wünsche T, Schürmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002;36:507-8.
46. Núñez M, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002;16:2352-4.
47. Ristig M, Crippin J, Aberg J, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-α and lamivudine therapy have failed. J Infect Dis 2002;186:1844-7.
48. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003;17:F7-F10.
49. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003;348:177-8.
50. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23.
51. Gish R, Leung N, Wang C, Corey L, Sacks S, Fried N, et al. Antiviral activity, safety and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years [abstract 383]. Hepatology 2002;36:372A.
52. Brook M, Gilson R, Wilkins E. British HIV Association. BHIVA guidelines: co-infection with HIV and chronic hepatitis B virus. HIV Med 2003;4 (Suppl 1):142-51.
53. Soriano V, Miró J, García-Samaniego J, et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004;11:2-17.
54. The EASL Jury. EASL International Consensus Statement Conference on Hepatitis B. J Hepatol 2003;38;533-40.